Noile-Immune Biotech Inc
TSE:4893
Noile-Immune Biotech Inc
Long-Term Debt
Noile-Immune Biotech Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
N
|
Noile-Immune Biotech Inc
TSE:4893
|
Long-Term Debt
ÂĄ0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Long-Term Debt
ÂĄ1.6B
|
CAGR 3-Years
102%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
||
PeptiDream Inc
TSE:4587
|
Long-Term Debt
ÂĄ17.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Takara Bio Inc
TSE:4974
|
Long-Term Debt
ÂĄ0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Pharma Foods International Co Ltd
TSE:2929
|
Long-Term Debt
ÂĄ1.1B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
116%
|
||
C
|
Cuorips Inc
TSE:4894
|
Long-Term Debt
ÂĄ0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Noile-Immune Biotech Inc
Glance View
Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
See Also
What is Noile-Immune Biotech Inc's Long-Term Debt?
Long-Term Debt
0
JPY
Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Long-Term Debt amounts to 0 JPY.